首页 正文

Dual inhibition with losartan and aliskiren: a promising therapeutic option for type 2 diabetic nephropathy?

{{output}}
This Practice Point commentary discusses the findings and limitations of a randomized, double-blind study conducted by Parving and colleagues. The study evaluated the renoprotective effects of dual blockade of the renin-angiotensin-aldosterone system by adding... ...